CRISPR Therapeutics Stock News

A couple of ARK Invest funds run by ETF star Cathie Wood made a huge buy on Friday.

Shares of leading gene editing company CRISPR Therapeutics (CRSP) are sliding on Friday. What's behind the slump?

CRISPR Therapeutics stock is now down roughly 33% across 2021's trading.

-Management to host conference call and webcast on October 12th at 4:30 p.m. ET-

CRISPR Therapeutics AG (CRSP) CEO Samarth Kulkarni Presents at Chardan's 5th Annual Genetic Medicines Conference Call Transcript

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $111.93, marking a +1.57% move from the previous day.

A stock market that soured on biotech stocks in general is presenting some bargain opportunities.

Editas Medicine Inc (NASDAQ: EDIT) has announced initial clinical data from the ongoing Phase 1/2 BRILLIANCE trial of EDIT-101 for blindness due to Leber congenital amaurosis 10 (LCA10), a CEP290-

Reasons To Buy Vertex Below $200

These top seven stocks among Cathie Wood's top holdings are ones investors may be enticed to consider right now. The post 7 Cathie Wood Stocks Every Growth Investor Needs In Their Portfolio appeared f

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $117.81, moving +0.48% from the previous trading session.

With drug pricing reform on the horizon, investors may want to analyze their allocation.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.

They're leaders in therapeutic areas with massive growth potential.

Gene editing stocks will take off as the underlying tech moves from fiction to fact and companies put their products on the market. The post 7 Gene Editing Stocks Promising to Change our DNA appeared